Nomura Healthcare Fund Class C (DLHCX)
| Fund Assets | 664.98M |
| Expense Ratio | 1.96% |
| Min. Investment | $1,000 |
| Turnover | 5.00% |
| Dividend (ttm) | 2.69 |
| Dividend Yield | 12.30% |
| Dividend Growth | -17.70% |
| Payout Frequency | Annual |
| Ex-Dividend Date | Dec 2, 2025 |
| Previous Close | 21.89 |
| YTD Return | -3.57% |
| 1-Year Return | 18.40% |
| 5-Year Return | 47.61% |
| 52-Week Low | 19.11 |
| 52-Week High | 25.75 |
| Beta (5Y) | n/a |
| Holdings | 108 |
| Inception Date | Jan 28, 2010 |
About DLHCX
Macquarie Healthcare Fund Class C is an actively managed mutual fund that targets the healthcare and biotechnology sectors. Its primary purpose is to achieve maximum long-term capital growth through capital appreciation by investing at least 80% of its assets in equity securities of companies involved in the development, production, or distribution of healthcare products and services. The fund holds a diversified portfolio of over 110 securities, with the top ten positions making up nearly half of its total assets. Macquarie Healthcare Fund Class C is structured to provide focused exposure to healthcare, an industry recognized for its significant long-term growth potential and resilience to economic cycles. The fund’s assets exceed $600 million and it features an expense ratio of approximately 1.96%. It distributes dividends annually, with a notably high recent dividend yield, reflecting its active approach to both growth and income within the evolving healthcare landscape. The fund caters to investors seeking specialized access to healthcare equities within a single, professionally managed vehicle, reinforcing its role as a sector-specific portfolio solution in the broader financial market.
Performance
DLHCX had a total return of 18.40% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.73%.
Top 10 Holdings
43.39% of assets| Name | Symbol | Weight |
|---|---|---|
| UCB SA | UCB | 5.51% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.22% |
| Pfizer Inc. | PFE | 4.50% |
| Gilead Sciences, Inc. | GILD | 4.45% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 4.28% |
| AbbVie Inc. | ABBV | 4.12% |
| AstraZeneca PLC | AZN | 3.91% |
| Eli Lilly and Company | LLY | 3.89% |
| Merck & Co., Inc. | MRK | 3.78% |
| Roche Holding AG | ROP | 3.73% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 2, 2025 | $2.6853 | Dec 2, 2025 |
| Dec 3, 2024 | $3.26278 | Dec 4, 2024 |
| Dec 4, 2023 | $1.31011 | Dec 5, 2023 |
| Dec 2, 2022 | $2.274 | Dec 5, 2022 |
| Dec 3, 2021 | $1.476 | Dec 6, 2021 |
| Dec 4, 2020 | $1.496 | Dec 7, 2020 |